HDAC2:阿尔茨海默病治疗靶点

表观调节机制在阿尔茨海默病的发生、发展过程中起着重要作用。乙酰化组蛋白和乙酰化非组蛋白在基因表达与信号转导过程中具有重要的调控作用。组蛋白去乙酰化酶抑制剂可以改善AD患者突触可塑性与学习记忆能力。HDAC2在控制神经元形成中起关键作用。HDAC2参与海马区域记忆形成相关蛋白表达,对学习和记忆的形成具有负调节作用,影响神经突触可塑性和数量。目前应用的HDAC抑制剂为广谱药物缺乏特异性,分析HDAC2作用机制有利于研究出针对疾病的靶点药物。     

组蛋白去乙酰化酶在肾脏疾病中的作用及机制

大量的临床和实验研究表明组蛋白去乙酰化酶(histone deacetylases, HDAC)介导的表观遗传调控在肾脏疾病的发生发展中发挥重要作用. HDAC是一类蛋白酶,通过维持与组蛋白乙酰转移酶(histone acetyl transferases,HAT)的动态平衡,在染色体重塑和基因的表达调控等方面发挥重要作用.本文总结了目前关于HDAC的分类、功能及其在肾脏疾病如糖尿病肾病、肾脏纤维化、急性肾损伤和多囊肾病中的作用和调控机制的最新进展.希望对HDAC介导的表观遗传调控的探讨和肾脏疾病的防治提供新的靶点和思路.     

组蛋白去乙酰化酶 6 及其选择性抑制剂的研究进展

组蛋白去乙酰化酶 6(HDAC6)是组蛋白去乙酰化酶(HDACs)IIb 家族中的一员,主要催化 α- 微管蛋白、热休克蛋白 Hsp90、皮质肌动蛋白及过氧化物还原酶等的去乙酰化。HDAC6 与肿瘤、神经退行性疾病、炎症、自身免疫应答、细菌感染及心脏病等 诸多疾病的病理生理进程密切相关,是一个极具应用前景的药物靶标。选择性 HDAC6 抑制剂是目前该领域的研究热点,有望克服广谱 HDAC 抑制剂存在的选择性差、副作用大等缺点。综述 HDAC6 的结构、生化功能、与疾病的关系及其选择性抑制剂的研究进展,为开发 新型选择性 HDAC6 抑制剂提供参考。     

小鼠组蛋白去乙酰化酶2多肽抗血清的制备

目的利用人工合成小鼠组蛋白去乙酰化酶2（histone deacetylase 2,HDAC2）多肽制备特异性抗HDAC2抗血清,用于相关疾病的体内外诊断。方法根据HDAC2基因编码的氨基酸序列合成多肽,与载体偶联后免疫动物,所制备的抗血清用ELISA、Western blot及免疫组织化学方法鉴定。结果 ELISA检测表明所制备的抗血清可同多肽抗原发生阳性反应,效价1∶4 000;Western blot结果显示抗血清可与多肽抗原及APP/PS1转基因小鼠的脑组织发生反应;免疫血清1∶100,1∶200,1∶400,1∶800四个稀释度均能与小鼠脑组织中的HDAC2反应。结论所制备的多肽抗血清可识别组织及血清中的HDAC2,可应用于相关领域的体内外研究。     

HDAC2 sumo-E3连接酶活性在DLD1细胞迁移和增殖中的作用

目的:探讨HDAC2 sumo-E3连接酶对DLD1细胞迁移与增殖的影响和可能机制。方法:全基因合成HDAC2 sumo-E3连接酶突变体HDAC2(325-488),并构建其重组慢病毒表达载体;感染DLD1hdac2-/-细胞(无内源性HDAC2表达),筛选稳定表HDAC2(325-488)的细胞克隆DLD1h325-488;RTCA实时细胞分析仪、Trans-well等检测DLD1h325-488稳定细胞的增殖和迁移能力;免疫印迹、q RT-PCR检测DLD1h325-488稳定细胞增殖和迁移相关基因的表达。结果:构建了稳定表达HDAC2 sumo-E3连接酶突变体HDAC2(325-488)的细胞株DLD1h325-488,并获得稳定表达HDAC2 sumo-E3连接酶突变体HDAC2(325-488)的DLD1h325-488细胞。与对照组细胞相比,DLD1h325-488细胞增殖活性无显著变化,但是细胞的迁移能力和迁移相关蛋白MMP14的表达显著上升。结论:HDAC2 sumo-E3连接酶可能通过上调mmp14的表达而促进DLD1细胞的迁移。     

组蛋白去乙酰化酶在间充质干细胞C3H10T1/2成脂分化过程中的表达及HDAC11的作用

组蛋白去乙酰化酶(histone deacetylase,HDAC)通过调节组蛋白乙酰化修饰参与调控基因表达.研究发现多种HDAC参与成脂分化,但其机制尚不清楚.本研究探讨间充质干细胞C3H10T1/2成脂分化过程中HDAC的表达变化及其对成脂分化的影响.本研究首先建立了C3H10T1/2体外成脂分化的模型,并以油红O染色鉴定成功诱导成脂分化.PCR检测C3H10T1/2细胞成脂分化过程中11种HDAC的变化趋势,发现成脂分化过程中,HDAC1、2、5、9和10的m RNA表达量下降,而HDAC3、6、8和11的m RNA表达量明显上升,其中HDAC11上升最为显著.进一步通过RNA干扰沉默HDAC11表达,PCR检测成脂分化的关键转录因子PPARγ2和成脂标志物Perilipin、Adipoq的m RNA表达量下降,但Fabp4表达变化不明显.油红O染色结果表明,诱导C3H10T1/2成脂分化过程中,干扰HDAC11表达,胞浆内脂滴形成数量减少,成脂分化受到抑制.实验结果提示,C3H10T1/2细胞成脂分化伴随着多种HDAC表达的变化,其中HDAC11的增加最显著,干扰HDAC11的表达可以抑制C3H10T1/2细胞的成脂分化.     

组蛋白去乙酰化酶（HDAC）在间充质干细胞C3H10T1/2成脂分化过程中的表达及HDAC11的作用

组蛋白去乙酰化酶（histone deacetylase, HDAC）通过参与调节组蛋白乙酰化修饰调控基因表达. 研究发现多种HDAC参与成脂分化,但其机制尚不清楚. 本研究旨在探讨间充质干细胞C3H10T1/2成脂分化过程中组蛋白去乙酰化酶（HDAC）的表达变化及其对成脂分化的影响. 本研究首先建立了C3H10T1/2体外成脂分化的模型并以油红O染色鉴定成功诱导成脂分化. PCR检测C3H10T1/2细胞成脂分化过程中11种HDAC的变化趋势,发现成脂分化过程中,HDAC1、2、5、9和10的mRNA表达量下降而HDAC3、6、8和11的mRNA表达量明显上升,其中HDAC11上升最为显著. 进一步通过RNA干扰沉默HDAC11表达, PCR检测成脂分化的关键转录因子PPARγ2和成脂标志物Perilipin、Adipoq 的mRNA表达量下降,但Fabp4表达变化不明显. 油红O染色结果表明,诱导C3H10T1/2成脂分化过程中,干扰HDAC11表达,胞浆内脂滴形成数量减少,成脂分化受到抑制. 总之,我们实验的结果提示C3H10T1/2细胞成脂分化伴随着多种HDAC表达的变化,其中HDAC11的增加最显著,干扰HDAC11的表达可以抑制C3H10T1/2细胞的成脂分化.     

组蛋白去乙酰化酶11的免疫调控功能及其在免疫相关疾病中的作用研究进展

组蛋白乙酰化是一种重要的表观遗传修饰,受到组蛋白乙酰转移酶和组蛋白去乙酰化酶的动态调节。组蛋白去乙酰化酶11 (histone deacetylases 11, HDAC11)是IV类HDAC的唯一成员,能够催化组蛋白和非组蛋白赖氨酸残基去乙酰化并具有去脂酰化活性。HDAC11与免疫细胞的成熟、分化和功能密切相关,多数研究显示HDAC11通过负调控IL-10和上调促炎细胞因子发挥免疫激活作用,但HDAC11也负调控中性粒细胞和T细胞的功能,发挥免疫抑制作用。最近报道HDAC11在炎症反应、肿瘤免疫、移植免疫、自身免疫疾病中发挥重要作用,是免疫治疗的重要靶点。该文就HDAC11的生物学特性、免疫调控功能、在免疫相关性疾病中的作用及其抑制剂开发的最新研究进展作一综述。     

组蛋白去乙酰化酶6与人类疾病

组蛋白去乙酰化酶6 (histone deacetylase 6, HDAC6)属于IIb类组蛋白去乙酰化酶家族,是一种依赖锌的,主要靶向非组蛋白的去乙酰化酶。越来越多的研究表明,HDAC6的表达和活性在多种疾病的发生发展过程中是异常的,因此,HDAC6被认为是潜在治疗的靶点。临床前数据表明,许多特异性靶向HDAC6的小分子抑制剂在多种疾病的治疗中发挥作用。该文讨论了HDAC6结构和功能的最新研究,并结合其小分子抑制剂在恶性肿瘤、神经退行性疾病、肾纤维化和自身免疫及炎症等方面的研究进展进行综述。     

组蛋白去乙酰化酶4与人类疾病北大核心CSCD

组蛋白去乙酰化酶4(histone deacetylase 4,HDAC4)是一类依赖锌的去乙酰化酶,属于Ⅱ类组蛋白去乙酰化酶(histone deacetylases,HDACs),主要具有去乙酰化酶的活性。HDAC4由去乙酰化酶结构域发挥去乙酰化酶的作用,还具有核定位序列和核输出序列,通过转录后与翻译后水平的修饰可在细胞核和细胞质之间穿梭,进而参与多种调节过程。近年来的研究发现,HDAC4可参与基因的转录调控、细胞凋亡、代谢等诸多生物进程,在多种疾病的发生发展中发挥重要作用。本文主要从HDAC4的结构、去乙酰作用、自身的修饰及其在核浆中的穿梭作用对其进行概述,同时对其在骨关节炎、心血管疾病、肌萎缩性侧索硬化症等不同疾病中的作用、相关的分子机制及组蛋白抑制剂在肿瘤中的应用等方面的研究进展进行综述。     

Radionuclide labeling and evaluation of candidate radioligands for PET imaging of histone deacetylase in the brain

Histone deacetylases (HDACs) regulate gene expression by inducing conformational changes in chromatin. Ever since the discovery of a naturally occurring HDAC inhibitor, trichostatin A (TSA) stimulated the recent development of suberoylanilide (SAHA, Zolinza®), HDAC has become an important molecular target for drug development. This has created the need to develop specific in vivo radioligands to study epigenetic regulation and HDAC engagement for drug development for diseases including cancer and psychiatric disorders. 6-([¹⁸F]Fluoroacetamido)-1-hexanoicanilide ([¹⁸F]FAHA) was recently developed as a HDAC substrate and shows moderate blood–brain barrier (BBB) permeability and specific signal (by metabolic trapping/or deacetylation) but rapid metabolism. Here, we report the radiosynthesis of two carbon-11 labeled candidate radiotracers (substrate- and inhibitor-based radioligand) for HDAC and their evaluation in non-human primate brain. PET studies showed very low brain uptake and rapid metabolism of both labeled compounds but revealed a surprising enhancement of brain penetration by F for H substitution when comparing one of these to [¹⁸F]FAHA. Further structural refinement is needed for the development of brain-penetrant, metabolically stable HDAC radiotracers and to understand the role of fluorine substitution on brain penetration.     

HDAC inhibitors in parasitic diseases

Parasitic diseases cause significant global morbidity and mortality, particularly in underdeveloped regions of the world. Malaria alone causes ~800000 deaths each year, with children and pregnant women being at highest risk. There is no licensed vaccine available for any human parasitic disease and drug resistance is compromising the efficacy of many available anti-parasitic drugs. This is driving drug discovery research on new agents with novel modes of action. Histone deacetylase (HDAC) inhibitors are being investigated as drugs for a range of diseases, including cancers and infectious diseases such as HIV/AIDS, and several parasitic diseases. This review focuses on the current state of knowledge of HDAC inhibitors targeted to the major human parasitic diseases malaria, schistosomiasis, trypanosomiasis, toxoplasmosis and leishmaniasis. Insights are provided into the unique challenges that will need to be considered if HDAC inhibitors are to be progressed towards clinical development as potential new anti-parasitic drugs.     

组蛋白去乙酰化酶4与人类疾病

组蛋白去乙酰化酶4（histone deacetylase 4,HDAC4）是一类依赖锌的去乙酰化酶,属于Ⅱ类组蛋白去乙酰化酶（histone deacetylases,HDACs）,主要具有去乙酰化酶的活性。HDAC4由去乙酰化酶结构域发挥去乙酰化酶的作用,还具有核定位序列和核输出序列,通过转录后与翻译后水平的修饰可在细胞核和细胞质之间穿梭,进而参与多种调节过程。近年来的研究发现,HDAC4可参与基因的转录调控、细胞凋亡、代谢等诸多生物进程,在多种疾病的发生发展中发挥重要作用。本文主要从HDAC4的结构、去乙酰作用、自身的修饰及其在核浆中的穿梭作用对其进行概述,同时对其在骨关节炎、心血管疾病、肌萎缩性侧索硬化症等不同疾病中的作用、相关的分子机制及组蛋白抑制剂在肿瘤中的应用等方面的研究进展进行综述。     

Blocking autophagy overcomes resistance to dual histone deacetylase and proteasome inhibition in gynecologic cancer

Histone deacetylase (HDAC) inhibitors and proteasome inhibitors have been approved by the FDA for the treatment of multiple myeloma and lymphoma, respectively, but have not achieved similar activity as single agents in solid tumors. Preclinical studies have demonstrated the activity of the combination of an HDAC inhibitor and a proteasome inhibitor in a variety of tumor models. However, the mechanisms underlying sensitivity and resistance to this combination are not well-understood. This study explores the role of autophagy in adaptive resistance to dual HDAC and proteasome inhibition. Studies focus on ovarian and endometrial gynecologic cancers, two diseases with high mortality and a need for novel treatment approaches. We found that nanomolar concentrations of the proteasome inhibitor ixazomib and HDAC inhibitor romidepsin synergistically induce cell death in the majority of gynecologic cancer cells and patient-derived organoid (PDO) models created using endometrial and ovarian patient tumor tissue. However, some models were not sensitive to this combination, and mechanistic studies implicated autophagy as the main mediator of cell survival in the context of dual HDAC and proteasome inhibition. Whereas the combination of ixazomib and romidepsin reduces autophagy in sensitive gynecologic cancer models, autophagy is induced following drug treatment of resistant cells. Pharmacologic or genetic inhibition of autophagy in resistant cells reverses drug resistance as evidenced by an enhanced anti-tumor response both in vitro and in vivo. Taken together, our findings demonstrate a role for autophagic-mediated cell survival in proteasome inhibitor and HDAC inhibitor-resistant gynecologic cancer cells. These data reveal a new approach to overcome drug resistance by inhibiting the autophagy pathway.Subject terms: Gynaecological cancer, Preclinical research     

Trichostatin A decreases the levels of MeCP2 expression and phosphorylation and increases its chromatin binding affinity

MeCP2 binds to methylated DNA in a chromatin context and has an important role in cancer and brain development and function. Histone deacetylase (HDAC) inhibitors are currently being used to palliate many cancer and neurological disorders. Yet, the molecular mechanisms involved are not well known for the most part and, in particular, the relationship between histone acetylation and MeCP2 is not well understood. In this paper, we study the effect of the HDAC inhibitor trichostatin A (TSA) on MeCP2, a protein whose dysregulation plays an important role in these diseases. We find that treatment of cells with TSA decreases the phosphorylation state of this protein and appears to result in a higher MeCP2 chromatin binding affinity. Yet, the binding dynamics with which the protein binds to DNA appear not to be significantly affected despite the chromatin reorganization resulting from the high levels of acetylation. HDAC inhibition also results in an overall decrease in MeCP2 levels of different cell lines. Moreover, we show that miR132 increases upon TSA treatment, and is one of the players involved in the observed downregulation of MeCP2.